Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation

Abstract

Whether thrombocytopenia substantively increases the risk of hemorrhage associated with anticoagulation in patients with atrial fibrillation (AF) is not established. The purpose of this study was to compare rates of bleeding in patients with AF and thrombocytopenia (platelet count < 100 000/μL) to patients with AF and normal platelet counts (>150 000/μL). We performed a propensity score-matched, retrospective cohort study of adults (n = 1070) with a new diagnosis of AF who received a prescription for an oral anticoagulant between 2015 and 2020. The thrombocytopenia cohort was defined as having at least 2 platelet counts <100 000/μL on separate days in the period spanning the 12 weeks preceding the initiation of anticoagulation to 6 weeks after the initiation of anticoagulation. The primary end point was the 1-year cumulative incidence of major bleeding; secondary end points included clinically relevant bleeding, arterial and venous thrombotic events, and all-cause mortality. Patients with AF and thrombocytopenia experienced a higher 1-year cumulative incidence of major bleeding (13.3% vs 5.7%; P < .0001) and clinically relevant bleeding (24.5% vs 16.7%; P = .005) than the controls. Thrombocytopenia was identified as an independent risk factor for major bleeding (hazard ratio, 2.20; confidence interval, 1.36-3.58; P = .001), with increasing risk based on the severity of thrombocytopenia. The cumulative incidence of arterial thrombosis at 1 year was 3.6% in the group with thrombocytopenia and 1.5% in controls (Gray test, P = .08). These findings suggest that baseline platelet counts are an important biomarker for hemorrhagic outcomes in AF and that the degree of thrombocytopenia is an important factor in determining the level of risk.

Graphical abstract

Figure 1.

Cumulative incidence of bleeding. One-year cumulative incidence of bleeding in patients with baseline thrombocytopenia vs in those with normal platelet counts. (A) Major bleeding. (B) Clinically relevant bleeding. Those with thrombocytopenia in red hashed lines and controls in solid blue.

Figure 2.

Cumulative incidence of thrombosis. One-year cumulative incidence of thrombosis in patients with baseline thrombocytopenia vs normal platelet counts. (A) Arterial thrombosis. (B) Venous thrombosis. Those with thrombocytopenia in red hashed lines and controls in solid blue.

Figure 3.

All-cause mortality. All-cause mortality in patients with baseline thrombocytopenia vs normal platelet counts. Those with thrombocytopenia in red and controls in blue.